AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30987664
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h continuous infusion, reduced to 1 mg/kg/h in postanesthesia care unit)
Trial: 26581881
Drug: Standard insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard insulin pump therapy (open-loop)
Trial: 16282436
Drug: GLU+FRUC (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLU+FRUC (1.0 g/min of GLU + 0.5 g/min of FRUC)
Trial: 16282436
Drug: GLU (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLU (1.5 g/min)
Trial: 7854793
Drug: Dextromethorphan 13.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 13.5 mg t.d.s.
Trial: 7854793
Drug: Dextromethorphan 27
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 27 mg t.d.s.
Trial: 21562412
Drug: Dexamethasone phosphate
RxNorm normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone phosphate (DP) 15 mg
Trial: 21562412
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate (MPA) 80 mg
Trial: 14521705
Drug: 0.005% calcipotriol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005% calcipotriol ointment applied twice a day
Trial: 14521705
Drug: 5% coal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% coal tar ointment applied overnight once daily
Trial: 10930152
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ddI
Trial: 9058316
Drug: low‐dose natural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low‐dose natural interferon‐alpha (nIFN alpha) for 6 months
Trial: 9058316
Drug: 6 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of maintenance chemotherapy (CAP)
Trial: 9058316
Drug: no maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no maintenance therapy (control group)
Trial: 8437528
Drug: Intravenous molsidomine
RxNorm normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous molsidomine (4 mg) on the first day
Trial: 8437528
Drug: Oral molsidomine
RxNorm normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral molsidomine (4 mg) on the first day
Trial: 8437528
Drug: Oral molsidomine
RxNorm normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral molsidomine (4 mg) on the second day
Trial: 8437528
Drug: Intravenous molsidomine
RxNorm normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous molsidomine (4 mg) on the second day
Trial: 20484968
Drug: Topical antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antioxidant pretreatment for 2 weeks
Trial: 10599726
Drug: Corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing hormone (CRH) infusion (1 microg/kg x h in saline)
Trial: 10599726
Drug: CRH infusion
RxNorm normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRH infusion
Trial: 18159577
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine administration
Trial: 1929450
Drug: UFT 400
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT 400 mg/day
Trial: 1929450
Drug: FT 600
RxNorm normalized name: FT-1101
DrugBank: FT-1101 (DB17553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FT 600 mg/day
Trial: 29040031
Drug: ATLG (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATLG (20 mg/kg per day on days -3, -2, -1)
Trial: 27121596
Drug: Lovaza (3.36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovaza (3.36 g daily for 1 year)
Trial: 24172159
Drug: Psychotropic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic medication use (lifetime and 12-month)
Trial: 24172159
Drug: Alternative medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alternative medicines
Trial: 19137353
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg triamcinolone acetonide (steroid group)
Trial: 19137353
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg sodium hyaluronate (hyaluronate group)
Trial: 11468606
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic ointment and occlusive patch over the affected eye (n=82)
Trial: 11468606
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic ointment 4 times a day without an occlusive patch (n=81)
Trial: 8149360
Drug: L-tyrosine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tyrosine (10 g/day in four divided doses)
Trial: 8149360
Drug: L-tyrosine
RxNorm normalized name: L-tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tyrosine
Trial: 2907520
Drug: L-bunolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-bunolol (2 mg)
Trial: 28415907
Drug: TPM/oxycodone patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPM/oxycodone patch
Trial: 18675742
Drug: Vehicle patch
RxNorm normalized name: EXYDERM Transdermal Vehicle Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle patch
Trial: 26121805
Drug: High-dose amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose amino acid administration (4 ml x kg(‐1) x hr(‐1))
Trial: 26121805
Drug: Low-dose amino
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amino acid administration (2 ml x kg(‐1) x hr(‐1))
Trial: 26121805
Drug: No amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No amino acid administration
Trial: 23278295
Drug: Home-use irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-use irradiation group using an LED device (420-nm blue light and 660-nm red light for 2.5 min twice daily for 4 weeks)
Trial: 19623014
Drug: siplizumab (0.012,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siplizumab (0.012, 0.04, 0.12, or 0.4 mg/kg)
Trial: 9041974
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg salbutamol sulfate with 0.5 mg ipratropium bromide
Trial: 9041974
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg salbutamol sulfate alone
Trial: 7705095
Drug: CVR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVR with 30 mcg EE
Trial: 7705095
Drug: CVR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVR with 65 mcg EE
Trial: 7705095
Drug: CVR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVR with 20 and 30 mcg EE
Trial: 7705095
Drug: NA/EE oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA/EE oral contraceptives
Trial: 7705095
Drug: EE/gestodene oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/gestodene oral contraceptives
Trial: 31792304
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy + anti-HER2
Trial: 31792304
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + anti-HER2
Trial: 22610153
Drug: FEC-D (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC-D (3 cycles of FEC100 followed by 3 cycles of 100 mg/m(2) docetaxel)
Trial: 15572415
Drug: T enanthate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T enanthate, 200 mg im every 2 weeks, with placebo pills daily (T-only)
Trial: 15572415
Drug: T enanthate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T enanthate, 200 mg every 2 weeks, with 5 mg finasteride daily (T + F)
Trial: 12477979
Drug: Noncontact normothermic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncontact normothermic wound therapy (NNWT)
Trial: 2195517
Drug: One-day antibiotic
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day antibiotic prophylaxis for major resections
Trial: 25908001
Drug: Standard-energy SLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-energy SLT treatment (270°)
Trial: 25908001
Drug: Sub-threshold energy
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-threshold energy SLT treatment (360°)
Trial: 12849809
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of rFSH
Trial: 12849809
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of rFSH
Trial: 11163812
Drug: Intramuscular 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 150 IU rFSH
Trial: 8021633
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of alcohol (blood concentration of 96mg/dL)
Trial: 22318383
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% tretinoin
Trial: 19622887
Drug: BoNT‐A (high-dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT‐A (high-dose)
Trial: 19622887
Drug: BoNT‐A (other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT‐A (other doses)
Trial: 7807627
Drug: Procaine penicillin
RxNorm normalized name: procaine penicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaine penicillin G intramuscularly for 10 days
Trial: 7807627
Drug: Benzathin penicillin
RxNorm normalized name: Penicillin G Benzathine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathin penicillin G combined with procaine penicillin G as a single dose intramuscularly
Trial: 2692189
Drug: Albendazole, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole, 400 mg (single dose)
Trial: 2692189
Drug: Mebendazole, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole, 600 mg (single dose)
Trial: 811102
Drug: Controlled-release nitroglycerin
RxNorm normalized name: nitroglycerin Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release nitroglycerin (2.6 mg tablets administered three times daily)
Trial: 11694668
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (traditional physical therapy at least every other week)
Trial: 31454023
Drug: Recombinant zoster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant zoster vaccine
Trial: 2672899
Drug: iv caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv caffeine 10 mg/kg
Trial: 1164878
Drug: B vitamins
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamins and anabolic steroid clostebol (Steranabol)
Trial: 25638752
Drug: Long-peptides plus
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-peptides plus TLR agonists
Trial: 25638752
Drug: Adaptive design
RxNorm normalized name: Designer Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive design for identifying optimal treatment strategy
Trial: 24355659
Drug: Full-dose iterative
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose iterative (FDI) image reconstruction
Trial: 24355659
Drug: Half-dose iterative
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose iterative (HDI) image reconstruction
Trial: 24355659
Drug: Full-dose standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose standard (FDS) image reconstruction
Trial: 21945081
Drug: High-dose bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bupivacaine
Trial: 19541736
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol (400 microg)
Trial: 11730442
Drug: High-dose aptiganel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aptiganel (5-mg bolus followed by 0.75 mg/h for 12 hours; n = 214)
Trial: 11730442
Drug: Low-dose aptiganel
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aptiganel (3-mg bolus followed by 0.5 mg/h for 12 hours; n = 200)
Trial: 8081045
Drug: C +
RxNorm normalized name: Probiotic + Colostrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C + R (chemotherapy with methotrexate, chlorambucil, vincristine, and cisplatin, given every 3 weeks)
Trial: 8081045
Drug: R (radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R (radiotherapy only, 50 Gy in the pelvis with a boost by external irradiation of the brachytherapy, cumulative dose of 68 Gy)
Trial: 29575526
Drug: JNJ‐42165279 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐42165279 (oral selective FAAH inhibitor)
Trial: 26033499
Drug: Locoregional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional therapy (LRT) combined with arsenic trioxide (As2 O3) at 10 mg/d for 4 courses (21 days per course) with a 2-week interval between courses
Trial: 26033499
Drug: Locoregional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional therapy (LRT) combined with arsenic trioxide (As2 O3)
Trial: 21570485
Drug: Treatment-as-usual (TAU)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (TAU) control
Trial: 18308112
Drug: Neoadjuvant chemohormonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemohormonal therapy (complete androgen blockage, docetaxel 70 mg/m2 on day 2, estramustine 280 mg three times daily on days 1 to 5 every 21 days) before radical prostatectomy.
Trial: 16799983
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (ADV) 10 mg once daily
Trial: 12542507
Drug: IFNbeta‐1a 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNbeta‐1a 30 mcg intramuscularly once weekly for 2 years
Trial: 9298051
Drug: 0.5% topical
RxNorm normalized name: Carac 0.5% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% topical ketorolac
Trial: 22506537
Drug: Betahistine 12
RxNorm normalized name: betahistine 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 12 mg
Trial: 11673338
Drug: Granulocyte-macrophage colony-stimulating
RxNorm normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF, Molgramostim) 40 microg intracoronary injection followed by 10 microg/kg subcutaneous for 2 weeks
Trial: 6101550
Drug: Behaviour Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour Therapy Programme (BTP)
Trial: 6101550
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Methadone Withdrawal Programme and Behaviour Therapy Programme (MBT)
Trial: 29021336
Drug: RAASi (renin-angiotensin-aldosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAASi (renin-angiotensin-aldosterone system inhibitors)
Trial: 26843962
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy group (ITG) with target HbA1c <6.2%, BP <120/75 mm Hg, LDL <80 mg/dL
Trial: 26843962
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy group (CTG) with target HbA1c <6.9%, BP <130/80 mm Hg, LDL <120 mg/dL
Trial: 24704117
Drug: Contigen (collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contigen (collagen gel)
Trial: 9741406
Drug: Neuromuscular blocking
RxNorm normalized name: Neuromuscular blocking agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular blocking agents (NMBA) and steroids
Trial: 3050336
Drug: Topical fusidic
RxNorm normalized name: fusidate Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fusidic acid 2% cream
Trial: 3050336
Drug: Oral dicloxacillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dicloxacillin 500 mg twice a day
Trial: 22925176
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (ferrous sulphate 200 mg tablets, 60 mg elemental iron, three times a day for 4 weeks)
Trial: 22925176
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (200 mg in divided doses on alternate days by slow intravenous infusion)
Trial: 2645796
Drug: Doxepin hydrochloride
RxNorm normalized name: Doxepin Hydrochloride
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxepin hydrochloride 150 mg (N = 9)
Trial: 31746819
Drug: Balloon Eustachian
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon Eustachian Tuboplasty with concurrent tympanocentesis
Trial: 30427274
Drug: Plavix (18.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plavix (18.75 mg PO q24h for 7 days)
Trial: 30427274
Drug: Generic clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic clopidogrel (18.75 mg PO q24h for 7 days)
Trial: 28571258
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of implant within two days of insertion
Trial: 28571258
Drug: Delayed loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed loading of implant after three months of insertion
Trial: 21145244
Drug: Phrenic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phrenic nerve infiltration (PNI) with 10 ml of 2% lidocaine
Trial: 21145244
Drug: Suprascapular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprascapular nerve block (SNB) with 10 ml of 0.5% plain bupivacaine
Trial: 17955789
Drug: OROS hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS hydromorphone once daily
Trial: 11286448
Drug: Metronidazole 400mg
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 400mg orally eight hourly for 5 days postoperatively
Trial: 9305320
Drug: Tolcapone 100
RxNorm normalized name: tolcapone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone 100 mg three times daily
Trial: 9305320
Drug: Tolcapone 200
RxNorm normalized name: tolcapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone 200 mg three times daily
Trial: 3732372
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of hydrochlorothiazide 25 mg and triamterene 50 mg
Trial: 3732372
Drug: Free combination
RxNorm normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free combination of furosemide 40 mg and triamterene 50 mg
Trial: 24760962
Drug: Ischemic postconditioning
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ischemic postconditioning (IPost) administered by 4 cycles of 1-minute reocclusion and 1-minute reperfusion, starting 1 minute after opening, followed by stenting.
Trial: 22301933
Drug: Higher-protein HMF
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-protein HMF (1.4 g protein/100 mL)
Trial: 22301933
Drug: Standard-protein HMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-protein HMF (1.0 g protein/100 mL)
Trial: 20842617
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence during the maintenance phase
Trial: 16170294
Drug: Serum progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Serum progesterone (P) levels on the day of human chorionic gonadotropin (hCG) administration
Trial: 10490789
Drug: (‐)‐HCA (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (‐)‐HCA (3.0 g/d)
Trial: 8526959
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia with sufentanil (15 micrograms initial bolus)